← Back to Analyst Consensus 
REGN Buy
REGENERON PHARMACEUTICALS, INC.
Current Price —
Implied Upside —
Analysts 37
30-Day Momentum
▲ 2 upgrades / ▼ 0 downgrades / 8 reiterations from 9 firms
Next Earnings
Oct 30, 2026 (3 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 21, 2026 | TD Cowen | maintain | Buy → Buy | $980 | 54% |
| Oct 19, 2026 | Piper Sandler | maintain | Overweight → Overweight | $865 | 54% |
| Oct 15, 2026 | UBS | upgrade | Neutral → Buy | $978 | 54% |
| Oct 8, 2026 | RBC Capital | maintain | Sector Perform → Sector Perform | $810 | 55% |
| Oct 7, 2026 | Truist Securities | maintain | Buy → Buy | $780 | 55% |
| Oct 7, 2026 | Morgan Stanley | maintain | Equal-Weight → Equal-Weight | $779 | 54% |
| Oct 6, 2026 | JP Morgan | maintain | Overweight → Overweight | $950 | 55% |
| Oct 1, 2026 | Jefferies | maintain | Buy → Buy | $930 | 52% |
| Oct 1, 2026 | Argus Research | upgrade | Hold → Buy | $850 | 54% |
| Sep 29, 2026 | RBC Capital | reiterate | Sector Perform → Sector Perform | $737 | 55% |
| Sep 10, 2026 | HSBC | maintain | Buy → Buy | $920 | 53% |
| Aug 17, 2026 | Leerink Partners | maintain | Market Perform → Market Perform | $824 | 51% |
| Aug 3, 2026 | Citigroup | maintain | Neutral → Neutral | — | 54% |
| Aug 3, 2026 | Guggenheim | maintain | Buy → Buy | $1,030 | 52% |
| Jul 31, 2026 | RBC Capital | maintain | Sector Perform → Sector Perform | $737 | 55% |
| Jul 31, 2026 | Morgan Stanley | maintain | Equal-Weight → Equal-Weight | $758 | 54% |
| Jul 31, 2026 | Cantor Fitzgerald | maintain | Overweight → Overweight | $795 | 50% |
| Jul 31, 2026 | Wells Fargo | maintain | Equal-Weight → Equal-Weight | $750 | 54% |
| Jul 31, 2026 | Truist Securities | maintain | Buy → Buy | $772 | 55% |
| Jul 21, 2026 | Guggenheim | maintain | Buy → Buy | $1,000 | 52% |
| Jul 9, 2026 | Piper Sandler | maintain | Overweight → Overweight | $854 | 54% |
| Jul 8, 2026 | Morgan Stanley | maintain | Equal-Weight → Equal-Weight | $730 | 54% |
| Jul 7, 2026 | RBC Capital | maintain | Sector Perform → Sector Perform | $696 | 55% |
| Jul 7, 2026 | Truist Securities | maintain | Buy → Buy | $769 | 55% |
| Jul 7, 2026 | Benchmark | upgrade | Hold → Buy | $185 | 54% |
| Jul 6, 2026 | HSBC | maintain | Buy → Buy | — | 53% |
| Jul 6, 2026 | Cantor Fitzgerald | maintain | Overweight → Overweight | $750 | 50% |
| May 19, 2026 | Canaccord Genuity | maintain | Buy → Buy | $875 | 48% |
| May 18, 2026 | BMO Capital | maintain | Outperform → Outperform | $730 | 53% |
| May 18, 2026 | Truist Securities | maintain | Buy → Buy | $778 | 55% |
| May 18, 2026 | JP Morgan | maintain | Overweight → Overweight | $850 | 55% |
| May 18, 2026 | Piper Sandler | maintain | Overweight → Overweight | $855 | 54% |
| May 18, 2026 | Wells Fargo | maintain | Equal-Weight → Equal-Weight | $700 | 54% |
| May 18, 2026 | RBC Capital | maintain | Sector Perform → Sector Perform | $707 | 55% |
| May 18, 2026 | Citigroup | downgrade | Buy → Neutral | $700 | 54% |
| May 18, 2026 | Leerink Partners | downgrade | Outperform → Market Perform | $641 | 51% |
| May 1, 2026 | Guggenheim | maintain | Buy → Buy | $995 | 52% |
| Apr 30, 2026 | RBC Capital | maintain | Sector Perform → Sector Perform | $762 | 55% |
| Apr 30, 2026 | Barclays | maintain | Overweight → Overweight | $917 | 53% |
| Apr 30, 2026 | Truist Securities | maintain | Buy → Buy | $796 | 55% |
| Apr 30, 2026 | Wells Fargo | maintain | Equal-Weight → Equal-Weight | $800 | 54% |
| Apr 23, 2026 | TD Cowen | maintain | Buy → Buy | $960 | 54% |
| Apr 23, 2026 | Cantor Fitzgerald | reiterate | Overweight → Overweight | $800 | 50% |
| Apr 10, 2026 | Morgan Stanley | maintain | Equal-Weight → Equal-Weight | $796 | 54% |
| Apr 8, 2026 | Bernstein | maintain | Outperform → Outperform | $921 | 52% |
| Mar 31, 2026 | Truist Securities | maintain | Buy → Buy | $801 | 55% |
| Mar 6, 2026 | Barclays | initiate | — → Overweight | $923 | 53% |
| Mar 2, 2026 | RBC Capital | maintain | Sector Perform → Sector Perform | $765 | 55% |
| Feb 9, 2026 | Guggenheim | maintain | Buy → Buy | $975 | 52% |
| Feb 2, 2026 | JP Morgan | maintain | Overweight → Overweight | $950 | 55% |
Price Target Trend
Aug 24, 2026 Oct 27, 2026
EPS Estimates
0q —
+1q —
0y —
+1y —
Cross-Platform Signals
No cross-platform signals in the last 90 days